Payment overview · 2025
General Payments
$1,637.30
87 reported records · 21 companies
Healthcare provider profile · identity verified
Mark O Sanders, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUGAR LAND, TX · NPI 1760417547
Verified facts
What the public records show
CMS Open Payments records show Mark O Sanders, MD received $1,637.30 in general payments during 2025 across 87 reported records.
Stryker Corporation accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $267.78 | 16.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.40 | 11.1% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.35 | 10.0% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.95 | 8.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.50 | 8.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.97 | 8.3% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.18 | 7.0% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.08 | 4.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.40 | 4.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.43 | 3.3% | 3 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $51.74 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.90 | 2.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.23 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.94 | 1.8% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.76 | 1.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.81 | 1.7% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $18.31 | 1.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.27 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.93 | 1.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.16 | 1.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $14.21 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,637.30 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $171.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $164.35 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $164.35 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $136.50 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $119.33 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $119.33 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.18 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $99.87 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $92.95 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.85 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.85 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $78.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.00 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.95 | 7 | 2025 |
Source payment records
|
|||||
| TRIATHLON Normalized: triathlon |
Device | Stryker Corporation | $57.54 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.64 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $38.44 | 1 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $38.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.10 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $28.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.62 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| TMC SPEEDTMT Normalized: tmc speedtmt |
Device | TREACE MEDICAL CONCEPTS, INC. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
122 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
50 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 934 | 246 |
| Amlodipine Besylate | Amlodipine Besylate | 871 | 251 |
| Atorvastatin Calcium | Atorvastatin Calcium | 663 | 186 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 625 | 176 |
| Losartan Potassium | Losartan Potassium | 516 | 147 |
| Alprazolam | Alprazolam | 411 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 395 | 60 |
| Metformin Hcl Er | Metformin Hcl | 393 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 109 |
| Lisinopril | Lisinopril | 363 | 105 |
| Tramadol Hcl | Tramadol Hcl | 335 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 92 |
| Zolpidem Tartrate | Zolpidem Tartrate | 273 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 255 | 66 |
| Meloxicam | Meloxicam | 233 | 77 |
| Montelukast Sodium | Montelukast Sodium | 226 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 91 |
| Methylprednisolone | Methylprednisolone | 208 | 170 |
| Metformin Hcl | Metformin Hcl | 207 | 58 |
| Gabapentin | Gabapentin | 206 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 56 |
| Pregabalin | Pregabalin | 196 | 58 |
| Glimepiride | Glimepiride | 194 | 53 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 176 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 51 |
| Celecoxib | Celecoxib | 173 | 47 |
| Bupropion Xl | Bupropion Hcl | 172 | 43 |
| Levofloxacin | Levofloxacin | 170 | 120 |
| Simvastatin | Simvastatin | 169 | 50 |
| Diclofenac Sodium Er | Diclofenac Sodium | 168 | 49 |
| Omeprazole | Omeprazole | 162 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 47 |
| Lorazepam | Lorazepam | 157 | 33 |
| Jardiance | Empagliflozin | 156 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 55 |
| Carvedilol | Carvedilol | 149 | 43 |
| Trazodone Hcl | Trazodone Hcl | 149 | 35 |
| Allopurinol | Allopurinol | 147 | 42 |
| Temazepam | Temazepam | 124 | 15 |
| Synthroid | Levothyroxine Sodium | 122 | 30 |
| Cefdinir | Cefdinir | 119 | 99 |
| Ozempic | Semaglutide | 119 | 24 |
| Furosemide | Furosemide | 113 | 40 |
| Atenolol | Atenolol | 112 | 28 |
| Azithromycin | Azithromycin | 109 | 88 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 36 |
| Alendronate Sodium | Alendronate Sodium | 106 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 99 | 62 |
| Clonidine Hcl | Clonidine Hcl | 98 | 26 |
| Sertraline Hcl | Sertraline Hcl | 96 | 28 |
| Finasteride | Finasteride | 95 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 28 |
| Myrbetriq | Mirabegron | 94 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 86 | 41 |
| Potassium Chloride | Potassium Chloride | 85 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 24 |
| Diazepam | Diazepam | 82 | 13 |
| Clonazepam | Clonazepam | 81 | 15 |
| Farxiga | Dapagliflozin Propanediol | 78 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 26 |
| Nifedipine Er | Nifedipine | 75 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 20 |
| Diclofenac Potassium | Diclofenac Potassium | 73 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 18 |
| Doxepin Hcl | Doxepin Hcl | 66 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 43 |
| Famotidine | Famotidine | 62 | 25 |
| Valsartan | Valsartan | 61 | 16 |
| Eliquis | Apixaban | 60 | 16 |
| Mounjaro | Tirzepatide | 60 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 59 | suppressed |
| Trulicity | Dulaglutide | 59 | 14 |
| Rybelsus | Semaglutide | 58 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Fenofibrate | Fenofibrate | 57 | 16 |
| Carisoprodol | Carisoprodol | 55 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 55 | 51 |
| Tresiba Flextouch U-200 | Insulin Degludec | 54 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 53 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 50 | 49 |
| Acyclovir | Acyclovir | 48 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 18 |
| Meclizine Hcl | Meclizine Hcl | 47 | 24 |
| Amoxicillin | Amoxicillin | 46 | 34 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Ketoconazole | Ketoconazole | 46 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 14 |
| Ondansetron Odt | Ondansetron | 45 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 15 |
| Fluconazole | Fluconazole | 43 | 23 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Lactulose | Lactulose | 40 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 28 |
| Telmisartan | Telmisartan | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Irbesartan | Irbesartan | 37 | 11 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 33 | suppressed |
| Glipizide | Glipizide | 33 | 12 |
| Premarin | Estrogens, Conjugated | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Linzess | Linaclotide | 31 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Ciclopirox | Ciclopirox | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Prednisone | Prednisone | 26 | 15 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 16 |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 13 |
| Ramipril | Ramipril | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Tadalafil | Tadalafil | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Levoxyl | Levothyroxine Sodium | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | 11 |
| Hydrocortisone | Hydrocortisone | 15 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | 11 |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,637.30 · 87 records | Stryker Corporation | ABRYSVO, AIRSUPRA, AREXVY, AUGMENT INJECTABLE, Auvelity, BREZTRI, COMIRNATY, CONTRAVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, GLYCATE, INCEPTIV, JARDIANCE, LINZESS, LOREEV XR, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROSTEP MICA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, SHINGRIX, TMC NANOPLASTY SYSTEM, TMC SPEEDTMT, TRELEGY ELLIPTA, TRIATHLON, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error